AIDSinfo - Drug Details

A Service of The U.S. Department of Health
and Human Services

Antiretroviral Drugs

Fusion Inhibitors

Enfuvirtide (Fuzeon, T-20)

Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Delavirdine (Rescriptor)

Efavirenz (Sustiva)

Nevirapine (Viramune)

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Abacavir (Ziagen)

Abacavir + Lamivudine (Epzicom)

Abacavir+Lamivudine+Zidovudine (Trizivir)

Didanosine (Videx, ddI)

Emtricitabine (Emtriva, FTC)

Emtricitabine + Tenofovir DF (Truvada)

Lamivudine (Epivir, 3TC)

Lamivudine+Zidovudine (Combivir)

Stavudine (Zerit, d4T)

Tenofovir DF (Viread)

Zalcitabine (Hivid, ddC)

Zidovudine (Retrovir, AZT, ZDV)

Protease Inhibitors (PIs)

Amprenavir (Agenerase)

Atazanavir (Reyataz)

Fosamprenavir (Lexiva, 908)

Indinavir (Crixivan)

Lopinavir+Ritonavir (Kaletra)

Nelfinavir (Viracept)

Ritonavir (Norvir)

Saquinavir (Fortovase, Invirase)

Home > Drugs > Viracept

Nelfinavir (Viracept)

Generic Name: Nelfinavir
Brand Name: Viracept

Nelfinavir mesylate, also known as Viracept, belongs to the class of antiretroviral drugs called protease inhibitors (PIs). PIs act by blocking protease, a protein that HIV needs to make more copies of itself.

AIDSinfo Drug Record for Nelfinavir

Search the Drug Database

Guidelines References to Nelfinavir

	Adult and Adolescent Guidelines
	Table 12: Characteristics of Protease Inhibitors (PIs)
	Table 14: Antiretroviral Dosing Recommendations in Patients with Renal or Hepatic Insufficiency
	Table 16: Potentially Life-Threatening and Serious Adverse Events
	Table 17: HIV-Related Drugs with Overlapping Toxicities
	Table 18: Adverse Drug Reactions and Related "Black Box Warnings" in Product Labeling for Antiretroviral Agents
	Table 19: Drugs That Should Not Be Used With PI or NNRTI Antiretrovirals
	Table 20: Drug Interactions Between Antiretrovirals and Other Drugs: PIs, NNRTIs, and NRTIs
	Table 21A: Drug Effects on Concentration of PIs
	Table 21B: Drug Effects on Concentration of NNRTIs
	Table 24: Novel Strategies To Consider For Treatment-Experienced Patients With Few Available Active Treatment Options
	Table 26: Suggested Minimum Target Trough Concentrations for Persons with Wild-Type HIV-1
	Table 28: Preclinical and Clinical Data Concerning the Use of Antiretrovirals During Pregnancy
	Table 29: Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy
	Table 5: Antiretroviral Regimens Recommended for Treatment of HIV-1 Infection in Antiretroviral Naive Patients
	Table 6: Advantages and Disadvantages of Antiretroviral Components Recommended as Initial Antiretroviral Therapy
	Table 7: Treatment Outcome of Selected Clinical Trials of Combination Antiretroviral Regimens in Treatment-Naïve Patients with 48-Week Follow-Up Data
	Pediatric Guidelines
	Appendix: Characteristics of Available Antiretroviral Drugs
	PI Drugs - Pediatrics
	Supplement: Pediatric Antiretroviral Drug Information
	Table 10: Advantages and Disadvantages of PIs for Use in Highly Active Antiretroviral Combination Regimens
	Table 11: Recommended Antiretroviral Regimens for Initial Therapy for HIV Infection in Children
	Perinatal Guidelines
	PI Drugs - Perinatal
	Table 2: Preclinical and Clinical Data Relevant to the Use of Antiretrovirals During Pregnancy
	Table 3: Antiretroviral Drug Use in Pregnant HIV-Infected Women: Pharmacokinetic and Toxicity Data in Human Pregnancy and Recommendations for Use in Pregnancy

Nelfinavir News

No related documents are currently available. Please check back soon. We are continually updating this area of our site.

More About Nelfinavir

	AIDSinfo Drug Record for Nelfinavir
	MEDLINEplus Fact Sheet on Nelfinavir
	Clinical Trials Using Nelfinavir
	Literature Citations for Nelfinavir
	more...